Von Hippel-Lindau disease (VHL) is an inherited disorder characterised by a predisposition to develop tumours in the eyes, central nervous system, kidneys, and adrenal glands. Recently the VHL gene was cloned and shown to be mutated in 75% of US and Canadian VHL families. To develop simple, rapid methods for the detection of mutations found in large numbers of affected people, we designed tests based on the primer specified restriction site modification method. These tests have proved useful in identifying asymptomatic mutated VHL gene carriers who have the nt 505 T to C mutation or the nt 686 T to C mutation. Together with an MspI digestion test which can detect a mutation hot spot in codon 238, polymerase chain reactionirestriction endonuclease based tests can now detect VHL mutations in more than 50% of VHL type 2 families. (J Med Genet 1995;32:938-941) 
The VHL families with point mutations that generated or destroyed unique restriction sites could be further tested for asymptomatic gene carriers by restriction enzyme digestion ofpolymerase chain reaction (PCR) products. However, point mutations in several families did not result in changes of restriction sites. Nt 505 T to C and nt 686 T to C were among the mutations which did not change a restriction site. Nt 505 T to C was found in 14 VHL families in the Black Forest area of Germany'5 and two families in the USA. 12 Mutation at nt 686 T to C was found in two large families in the USA.'2 There were more than 100 patients with the 505 mutation and more than 75 (table) . In summary, we described a convenient method of detecting point mutations at nt 505 T to C and nt 686 T to C in the VHL gene and its possible role for the screening of subjects in VHL type 2 families.
